GlobeNewsWire
17 Nov 2026, 21:45 UTC · 4h ago
Biogen's Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer's Disease
Impact · against what's priced in
Biogen's positive Phase 2 data for diranersen introduces a new growth catalyst not currently accounted for in the valuation. While the market is focused on LEQEMBI's delivery methods and China expansion, this tau-targeting therapy adds a separate pipeline win that could improve long-term revenue CAGR beyond the assumed 4.7%.
- BIIB+0.40
Not in the price yet
- In context
The market is currently focused on LEQEMBI's autoinjector and zorevunersen; the slowing of clinical decline in early Alzheimer's via diranersen represents a new, separate pipeline driver not listed in the current price assumptions.





